Investigational positive inotropic agents for acute heart failure

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 3, 2009, Pages 193-205

  Tamargo, Juan ^a   Caballero, Ricardo ^a   Gómez, Ricardo ^a   Barana, Adriana ^a   Amorós, Irene ^a   Delpón, Eva ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Acute heart failure; CK 1827452; Inotropic drugs; Istaroxime; Levosimendan

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; AMRINONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM SENSITIZER; CATECHOLAMINE; DENOPAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENOXIMONE; INOTROPIC AGENT; ISTAROXIME; LEVOSIMENDAN; LOPRINONE; MILRINONE; NITRATE; NORADRENALIN; PHOSPHODIESTERASE III INHIBITOR; PIPERANOMETOZINE; PLACEBO; PST 2744; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE AGENT; VASODILATOR AGENT;

ACUTE HEART FAILURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY DISEASE; CYTOSOL; DISEASE CLASSIFICATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART DEATH; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; HYPOTENSION; LOW DRUG DOSE; MORTALITY; NAUSEA; NONHUMAN; PAIN; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; ANIMALS; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HEART FAILURE; HUMANS;

EID: 73249114314     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909789007070     Document Type: Review

References (82)

1. Nieminen, M.S.; Böhm, M.; Cowie, M.R.; Drexler, H.; Filippatos, G.S.; Jondeau, G.; Hasin, Y.; Lopez-Sendon, J.; Mebazaa, A.; Metra, M.; Rhodes, A.; Swedberg, K.; Priori, S.G.; Garcia, M.A.; Blanc, J.J.; Budaj, A.; Cowie, M.R.; Dean, V.; Deckers, J.; Burgos, E.F.; Lekakis, J.; Lindahl, B.; Mazzotta, G.; Morais, J.; Oto, A.; Smiseth, O.A.; Garcia, M.A.; Dickstein, K.; Albuquerque, A.; Conthe, P.; Crespo-Leiro, M.; Ferrari, R.; Follath, F.; Gavazzi, A.; Janssens, U.; Komajda, M.; Morais, J.; Moreno, R.; Singer, M.; Singh, S.; Tendera, M.; Thygesen, K.; for the ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J., 2005, 26, 384-416.
2. Gheorghiade, M.; Zannad, F.; Sopko, G.; Klein, L.; Piña, I.L.; Konstam, M.A.; Massie, B.M.; Roland, E.; Targum, S.; Collins, S.P.; Filippatos, G.; Tavazzi, L.; International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation, 2005, 112, 3958-3968.
3. Adams, K.F.; Lindenfeld, J.; Arnold, J.; et al. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J. Card. Fail., 2006, 12, 10-38.
4. Dickstein, K.; Cohen-Solal, A.; Filippatos, G.; McMurray, J.J.; Ponikowski, P.; Poole-Wilson, P.A.; Strömberg, A.; van Veldhuisen, D.J.; Atar, D.; Hoes, A.W.; Keren, A.; Mebazaa, A.; Nieminen, M.; Priori, S.G.; Swedberg, K.; ESC Committee for Practice Guidelines, Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J., 2008, 29, 2388-2442.
5. Fonarow, G.C.; Adams, K.F.; Jr.; Abraham, W.T.; Yancy, C.W.; Boscardin, W.J. for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry. JAMA, 2005, 293, 572-580.
6. Alla, F.; Zannad, F.; Filippatos, G. Epidemiology of acute heart failure syndromes. Heart Fail. Rev., 2007, 12, 91-95.
7. Rudiger, A.; Harjola, V.P.; Müller, A.; Mattila, E.; Säila, P.; Nieminen, M.; Follath, F. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur. J. Heart Fail., 2005, 7, 662-670.
8. Nieminen, M.S.; Hariola, V.P. Definition and epidemiology of acute heart failure syndromes. Am. J. Cardiol., 2005, 96 (Suppl), 5G-10G.
9. Gheorghiade, M.; Abraham, W.T.; Albert, N.M.; Greenberg, B.H.; O'Connor, C.M.; She, L.; Stough, W.G.; Yancy, C.W.; Young, J.B.; Fonarow, G.C.; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA, 2006, 296, 2217-2226.
10. Bundkirchen, A.; Scwinger, R.H.G. Epidemiology and economic burden of chronic heart failure. Eur. Heart J. Suppl., 2004, 6(Suppl D), D57-D60.
11. Zannad, F.; Mebazaa, A.; Juillière, Y.; Cohen-Solal, A.; Guize, L.; Alla, F.; Rougé, P.; Blin, P.; Barlet, M.H.; Paolozzi, L.; Vincent, C.; Desnos, M.; Samii, K.; EFICA Investigators. EFICA Investigators. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur. J. Heart Fail., 2006, 8, 697-705.
12. Fonarow, G.C. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev. Cardiovasc. Med., 2003, 4 (Supplement 7), S21-S30.
13. Fonarow, G.C.; Abraham, W.T.; Albert, N.M.; et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am. Heart J., 2004, 148, 43-51.
14. Nieminen, M.S.; Brutsaert, D.; Dickstein, K.; Drexler, H.; Follath, F.; Harjola, V.P.; Hochadel, M.; Komajda, M.; Lassus, J.; Lopez-Sendon, J.L.; Ponikowski, P.; Tavazzi, L; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur. Heart J., 2006, 27, 2725-2736.
15. Tavazzi, L.; Maggioni, A.P.; Lucci, D.; Cacciatore, G.; Ansalone, G.; Oliva, F.; Porcu, M.; Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur. Heart J., 2006, 27, 1207-1215.
16. Siirilia-Waris, K.; Lassus, J.; Melin, J.; Peuhkurinene, K.; Nieminen, M.S.; Harjola, V.P. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur. Heart J., 2006, 27, 3011-3017.
17. Parissis, J.T.; Farmakis, D.; Nieminen, M. Classical inotropes and new cardiac enhancers. Heart Fail. Rev., 2007, 12, 149-156.
18. Bers, D.M. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol., 2008, 70, 23-49.
19. Katz, A. Physiology of the heart, Lippincott Williams & Wilkins: Philadelphia, 2009.
20. Solaro, R.J.; Rarick, H.M. Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. Circ. Res., 1998, 83, 471-480.
21. Felker, G.M.; Benza, R.L.; Chandler, A.B.; Leimberger, J.D.; Cuffe, M.S.; Califf, R.M.; Gheorghiade, M.; O'Connor, C.M.; The OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol., 2003, 41, 997-1003.
22. Thackray, S.; Easthaugh, J.; Freemantle, N.; Cleland, J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur. J. Heart Fail., 2002, 4, 515-529.
23. Stevenson, L. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation, 2003, 108, 367-372.
24. Bayram, M.; De Luca, L.; Massie, M.B.; Gheorghiade, M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am. J. Cardiol., 2005, 96, 47G-58G.
25. De Luca, L.; Mebazaa, A.; Filippatos, G.; Parissis, J.T.; Böhm, M.; Voors, A.A.; Nieminen, M.; Zannad, F.; Rhodes, A.; El-Banayosy, A.; Dickstein, K.; Gheorghiade, M. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur. J. Heart Fail., 2008, 10, 201-213.
26. Abraham, W.T.; Adams, K.F.; Fonarow, G.C.; Costanzo, M.R.; Berkowitz, R.L.; LeJemtel, T.H.; Cheng, M.L.; Wynne, J. The ADHERE Scientific Advisory Committee and Investigators and ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol., 2005, 46, 57-64.
27. O'Connor, C.M.; Gattis, W.A.; Uretsky, B.F.; Adams, K.F.; Jr, McNulty, S.E.; Grossman, S.H.; McKenna, W.J.; Zannad, F.; Swedberg, K.; Gheorghiade, M.; Califf, R.M. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J., 1999, 138, 78-86.
28. Elkayam, U.; Tasissa, G.; Binanay, C.; Stevenson, L.W.; Gheorghiade, M.; Warnica, J.W.; Young, J.B.; Rayburn, B.K.; Rogers, J.G.; DeMarco, T.; Leier, C.V. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am. Heart J., 2007, 153, 98-104.
29. Amsallem, E.; Kasparian, C.; Haddour, G.; Boissel, J.P.; Nony, P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst. Rev., 2005, 1, CD002230
30. Fonarow, G.C.; Stough, W.G.; Abraham, W.T.; Albert, N.M.; Gheorghiade, M.; Greenberg, B.H.; O'Connor, C.M.; Sun, J.L.; Yancy, C.W.; Young, J.B.; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol., 2007, 50, 768-777.
31. Cleland, J.G.; Pennell, D.J.; Ray, S.G.; Coats, A.J.; Macfarlane, P.W.; Murray, G.D.; Dalle M.J, Vered, Z.; Lahiri, A. Carvedilol hibrenating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of ejection fraction response to carvediol in patients with heart failure (CHRISTMAS trial): randomized control trial. Lancet, 2003, 362, 14-21.
32. Bart, B.A.; Shaw, L.K.; McCants, C.B.; Jr, Fortin, D.F.; Lee, K.L.; Califf, R.M.; O'Connor, C.M. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or non-ischemic cardiomyopathy. J. Am. Coll. Cardiol., 1997, 30, 1002-1008.
33. Gheorghiade, M.; De Luca, L.; Bonow, R.O. Neurohormonal Inhibition in heart failure: insights from recent clinical trials. Am. J. Cardiol., 2005, 96, 3L-9L.
34. Schulz, R.; Rose, J.; Martin, C.; Brodde, O.E.; Heusch, G. Development of short-term myocardial hibernation: its limitation by the severity of ischemia and inotropic stimulation. Circulation, 1993, 88, 684-695.
35. Elsässer, A.; Schlepper, M.; Klövekorn, W.P.; Cai, W.J.; Zimmermann, R.; Müller, K.D.; Strasser, R.; Kostin, S.; Gagel, C.; Münkel, B.; Schaper, W.; Schaper, J. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation, 1997, 96, 2920-2931.
36. Burger, A.J.; Elkayam, U.; Neibaur, M.T.; Haught, H.; Ghali, J.; Horton, D.P.; Aronson, D.Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am. J. Cardiol., 2001, 88, 35-39.
37. Haikala, H.; Nissinen, E.; Etemadzadeh, E.; Levijoki, J.; Linden, I.B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. Pharmacol., 1995, 25, 794-801.
38. De Luca, L.; Colucci, W.S.; Nieminen, M.S.; Massie, B.M.; Gheorghiade, M. Evidence-based use of levosimendan in different clinical settings. Eur. Heart J., 2006, 27, 1908-1920.
39. Antoniades, C.; Tousoulis, D.; Koumallos, N.; Marinou, K.; Stefanadis, C. Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol. Ther., 2007, 114, 184-97.
40. Tachibana, H.; Cheng, H.J.; Ukai, T.; Igawa, A.; Zhang, Z.S.; Little, W.C.; Cheng, C.P. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H914-922.
41. Sonntag, S.; Sundberg, S.; Lehtonen, L.A.; Kleber, F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J. Am. Coll. Cardiol., 2004, 43, 2177-2182.
42. Parissis, J.T.; Panou, F.; Farmakis, D.; Adamopoulos, S.; Filippatos, G.; Paraskevaidis, I.; Venetsanou, K.; Lekakis, J.; Kremastinos, D.T. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am. J. Cardiol., 2005, 96, 423-426.
43. Kersten, J.R.; Montgomery, M.W.; Pagel, P.S.; Warltier, D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth. Analg., 2000, 90, 5-11.
44. Yokoshiki, H.; Sperelakis, N. Vasodilating mechanisms of levosimendan. Cardiovasc. Drugs Ther., 2003, 17, 111-113.
45. O'Rourke, B. Myocardial K(ATP) channels in preconditioning. Circ. Res., 2000, 87, 845-855.
46. Maytin, M.; Colucci, W.S. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am. J. Cardiol., 2005, 96, 26G-31G.
47. Antila, S.; Sundberg, S.; Lehtonen, L.A. Clinical pharmacology of levosimendan. Clin. Pharmacokinet., 2007, 46, 535-552.
48. Kivikko, M.; Antila, S.; Eha, J.; Lehtonen, L.; Pentikainen, P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int. J. Clin. Pharmacol. Ther., 2002, 40, 465-471.
49. Nieminen, M.S.; Akkila, J.; Hasenfuss, G.; Kleber, F.X.; Lehtonen, L.A.; Mitrovic, V.; Nyquist, O.; Remme, W.J. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol., 2000, 36, 1903-1912.
50. Slawsky, M.T.; Colucci, W.S.; Gottlieb, S.S.; Greenberg, B.H.; Haeusslein, E.; Hare, J.; Hutchins, S.; Leier, C.V.; LeJemtel, T.H.; Loh, E.; Nicklas, J.; Ogilby, D.; Singh, B.N.; Smith, W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation, 2000, 102, 2222-2227.
51. Follath, F.; Cleland, J.G.; Just, H.; Papp, J.G.; Scholz, H.; Peuhkurinen, K.; Harjola, V.P.; Mitrovic, V.; Abdalla, M.; Sandell, E.P.; Lehtonen, L. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet, 2002, 360, 196-202.
52. Michaels, A.D.; McKeown, B.; Kostal, M.; Vakharia, K.T.; Jordan, M.V.; Gerber, I.L.; Foster, E.; Chatterjee, K. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation, 2005, 111, 1504-1509.
53. Kyrzopoulos, S.; Adamopoulos, S.; Parissis, J.T.; Rassias, J.; Kostakis, G.; Iliodromitis, E.; Degiannis, D.; Kremastinos, DT. Levosimendan reduces plasma B-type natriuretic peptide and interleukin-6, and improves central hemodynamics in severe heart failure patients. Int. J. Cardiol., 2005, 99, 409-413.
54. Nicklas, J.M.; Monsur, J.C.; Bleske, B.E. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am. J. Cardiol., 1999, 83, 12I-15I.
55. Toivonen, L.; Viitasalo, M.; Sundberg, S.; Akkila, J.; Lehtonen, L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J. Cardiovasc. Pharmacol., 2000, 35, 664-669.
56. Mebazaa, A.; Nieminen, M.S.; Packer, M.; Cohen-Solal, A.; Kleber, F.X.; Pocock, S.J.; Thakkar, R.; Padley, R.J.; Põder, P.; Kivikk, M; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA, 2007, 297, 1883-1891.
57. Cleland, J.G.; Freemantle, N.; Coletta, A.P.; Clark, A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail., 2006, 8, 105-110.
58. Moiseyev, V.S.; Põder, P.; Andrejevs, N.; Ruda, M.Y.; Golikov, A.P.; Lazebnik, L.B.; Kobalava, Z.D.; Lehtonen, L.A.; Laine, T.; Nieminen, M.S.; Lie, K.I.; RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J., 2002, 23, 1422-1432.
59. Zairis, M.N.; Apostolatos, C.; Anastasiadis, P. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO). J. Am. Coll. Cardiol., 2004, 43 (Supplement 1), 206A-207A.
60. Packer, M.; Colucci, W.S.; Fisher, L.; Massie, B.M.; Teerlink, J.R.; YOUNG, J.B.; Garratt, C.J. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure results with levosimendan in the REVIVE-1 study. J. Card. Fail., 2003, 9, S61.
61. Johansson, S.; Apajasalo, M.; Sarapohja, T.; Garratt, C. Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study [abstract]. Crit. Care, 2004, 8 (Suppl 1), P88.
62. Packer, M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials. Dallas, TX: American Heart Association, Annual Scientific Session; November 2005 pg. 13-6.
63. + pump inhibition: evaluation of electrophysiological mechanisms. J. Pharmacol. Exp. Ther., 2003, 305, 765-771.
64. Micheletti, R.; Mattera, G.G.; Rocchetti, M.; Schiavone, A.; Loi, M.F.; Zaza, A.; Gagnol, R.J.P.; De Munari, S.; Melloni, P.; Carminati, P.; Bianchi, G.; Ferrari, P. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J. Pharmacol. Exp. Ther., 2002, 303, 592-600.
65. Adamson, P.B.; Vanoli, E.; Mattera, G.G.; et al. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure. J. Cardiovasc. Pharmacol., 2003, 42, 169-173.
66. Sabbah, H.N.; Imai, M.; Cowart, D.; Amato, A.; Carminati, P.; Gheorghiade, M. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am. J. Cardiol., 2007, 99, 41A-46A
67. Mattera, G.G.; Lo Giudice, P.; Loi, F.M.; Vanoli, E.; Gagnol, J.P.; Borsini, F.; et al. Istaroxime: a new lusoinotropic agent for heart failure. Am. J. Cardiol., 2007, 99, S33-40.
68. Ghali, J.K.; Smith, W.B.; Torre-Amione, G.; Haynos, W.; Rayburn, B.K.; Amato, A.; Zhang, D.; Cowart, D.; Valentini, G.; Carminati, P.; Gheorghiade, M. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure and reduced systolic function. J. Am. Coll. Cardiol., 2007, 99, 47A-56A.
69. Gheorghiade, M.; Blair, J.E.; Filippatos, G.S.; Macarie, C.; Korewicki, J.; Bubenek-Turconi, S.I.; Ceracchi, M.; Bianchetti, M.; Carminati, P.; Kremastinos, D.; Valentini, G.; Sabbah, H.N.; HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J. Am. Coll. Cardiol., 2008, 51, 2276-2285.
70. Shen, Y.T.; Vatner, S.F.; Morgans, D.J.; Malik, F. Activating cardiac myosin, a novel inotropic mechanism to improve cardiac function in conscious dogs with congestive heart failure. J. Card. Fail., 2006, 12, S87.
71. Anderson, R.L.; Sueoka, S.H.; Rodriguez, H.M.; Lee, K.; Cox, D.R.; Kawas, R.; Godinez, G.; Morgan, B.P.; Sakowicz, R.; Morgans, D.J.; Malik, F.; Elias, K.A. In vitro and in vivo efficacy of the cardiac myosin activator CK-1827452. J. Cardiac. Fail., 2006, 12, S86.
72. Malik, F.; Teerlink, J.R.; Escandon, R.; Clarke, C.P.; Wolff, A.A. The Selective Cardiac Myosin Activator, CK-1827452, a calcium-independent inotrope, increases left ventricular systolic function by increasing ejection time rather than the velocity of contraction. Circulation, 2006, 114, II-441.
73. Teerlink, J. R. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail. Rev., 2009; Feb 21. [Epub ahead of print].
74. Anderson, R.L.; Sueoka, S.H.; Lee, K.H.; et al. In vitro and in vivo characterization of CK-1827452, a selective cardiac myosin activator. J. Cardiac. Fail., 2006, 12 (Suppl), S86.
75. Anderson, R.; Pokrovskii, M.; Elias, K. Effects of Cardiac Myosin Activators on Excitation-Contraction (E-C) Coupling in Ventricular Myocytes. 2007 Biophysical Society Meeting Abstracts. Biophys. J., 2007, Suppl: 133A.
76. Malik, F.; Elias, K.A.; Finer, J.T.; Morgan, B.P.; Sakowicz, R.; Anderson, R.; Baliga, R.; Conn, L.; Cox, D.; Garard, M.; Hartman, J.; Irvine, J.; Kawas, R.; Kraynack, E.; Kuklov, A.; Lee, K.H.; Lu, P.; Muci, D.; Pierce, D.W.; Rodriguez, H.; Suehiro, I.; Sueoka, S.H.; Sylvester, S.; Tochimoto, T.; Valdez, C.; Wang, W.; Katori, T.; Kass, D.A.; Shen, Y.T.; Vatner, S.F.; Morgans, D.J. Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. J. Card. Fail., 2005, 11 (suppl), S95.
77. Shen, Y.; Zhang, Y.; Morgans, D.J.; Vatner, S.F.; Malik, F. A novel inotropic agent that activates cardiac myosin and increases cardiac contractility without increasing MVO2 in heart failure with left ventricular hypertrophy. J. Am. Coll. Cardiol., 2008, 51 (Suppl), A54.
78. Teerlink, J.R.; Malik, F.I.; Clarke, C.P.; Saikali, K.; Escandon, R.; Lee, J.H.; Wolff, A.A. The selective cardiac myosin activator CK-1827452, a calcium-independent inotrope, increases LV systolic function by increasing ejection time: results of a first-in-human study of a unique and novel mechanism. J. Card. Fail., 2006, 12, 763.
79. Malik, F.; Saikai, K.G.; Clarke, C.O.; Teerlink, J.R.; Wolff, A.A. Systolic ejection time is a sensitive indicator of left ventricular systolic function during treatment with the selective cardiac myosin activator, CK-1827452. J. Cardiac. Fail., 2007, 13 (Suppl 2), S145-S146.
80. Cleland, J.G.F.; McMurray, J.J.; Lang, C.C.; et al. First clinical trial of the selective cardiac myosin activator, CK-1827452, in heart failure: effect of dose and plasma concentration on systolic function. Eur. Heart J., 2008, 29(Abstract Suppl), 299.
81. Senior, R.; Malik, F.; Saikali, K.; Lee, J.; Brand, G.; Wolff, A.A. The selective cardiac myosin activator, CK-1827452, increases systolic function in a concentration-dependent manner in patients with stable heat failure. J. Am. Coll. Cardiol., 2009; 53: A160.
82. Jerling, M.; Chew, T.; Escandon, R.; Lee, J.; Saikali, K.; Venables, E.; Clarke, C.; Malik, F.; Wolff, A. Oral bioavailability of the selective cardiac myosin activator ck-1827452: chronic oral inotropic therapy for heart failure? J. Cardiac. Fail., 2007, 13, S148 .